We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease, it is the first allogeneic cell therapy product to be approved for commercial use in India.
As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from Pharmaceuticals and Medical Devices Agency.
Stempeutics Research has announced that it has signed a strategic deal with Kemwell Biopharma for global commercialisation of its stem cell product Stempeucel.
Biotech firm Stempeutics Research has inked an out-licensing deal with drug major Cipla for its stem cell therapy product Stempeucel, indicated for treating critical limb ischemia. “